
Pharmacy Week in Review: Narcolepsy Drug Approved for Children, Thyroid Disease Linked to RA Onset
A look at last week's top stories in the world of pharmacy.
A look at last week's top stories in the world of pharmacy.
Transcript
Hello and welcome to the Pharmacy Times News Network. I’m Nicole Grassano your host for our Pharmacy Week in Review.
FDA officials have approved Jazz Pharmaceuticals' Xyrem to treat cataplexy and excessive daytime sleepiness in pediatric patients aged 7 to 17 years with narcolepsy,
The FDA is reminding health care professionals who prescribe and dispense antibiotics that there are recent safety labeling changes for systemic fluoroquinolones,
The risk of autoimmune thyroid disease (AITD) increases during the 5-year period before diagnosis of rheumatoid arthritis (RA) but appears to drop following RA diagnosis, according to a new study,
Pharmacists may get more questions about Eliquis if their patients have seen a new commercial for the prescription medication. In the spot, called “Around the Corner,” after a woman has a blood clot caused by deep vein thrombosis (DVT), she worries that another one may be around the corner. According to the commercial, she protects herself with Eliquis, which has been proven to prevent and treat DVT blot clots, while causing less major bleeding than Lovenox. This allows her to enjoy exploring nature with her husband and spending time with her granddaughter.
For more great coverage and practical information for today’s pharmacist, visit our website and sign up for our Daily eNews. And don’t forget to follow us on Facebook, Twitter, and Instagram.
Thanks for watching our Pharmacy Week in Review. I’m Nicole Grassano at the Pharmacy Times News Network.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.